Share This Page
Drug Price Trends for NDC 59651-0824
✉ Email this page to a colleague
Average Pharmacy Cost for 59651-0824
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CIMETIDINE 300 MG TABLET | 59651-0824-01 | 0.25824 | EACH | 2025-12-17 |
| CIMETIDINE 300 MG TABLET | 59651-0824-01 | 0.26243 | EACH | 2025-11-19 |
| CIMETIDINE 300 MG TABLET | 59651-0824-01 | 0.26648 | EACH | 2025-10-22 |
| CIMETIDINE 300 MG TABLET | 59651-0824-01 | 0.27049 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 59651-0824
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 59651-0824
Introduction
The pharmaceutical landscape for NDC 59651-0824, a recently approved or emerging drug, warrants a detailed market analysis and forward-looking price projections. Understanding the strategic positioning, competitive environment, and pricing trends is crucial for stakeholders, including manufacturers, healthcare providers, and investors. This report synthesizes current market data, historical pricing cues, regulatory status, and potential growth trajectories to inform decision-making.
Drug Profile and Therapeutic Area
NDC 59651-0824 corresponds to a specific medicinal product, identified by its unique National Drug Code. Based on available data, it belongs to the [specify therapeutic area, e.g., autoimmune, oncology, neurology], addressing [conditions or indications]. The therapeutic class's dynamics influence market penetration, reimbursement, and pricing strategies[1].
Regulatory and Market Entry Context
The drug’s approval status significantly impacts its market outlook. A recent FDA or international approval can catalyze initial uptake, contingent upon the extent of clinical benefit and unmet medical need[2]. Moreover, patent exclusivity, orphan drug designation, or expedited approval pathways could modify market access and pricing flexibility.
Competitive Landscape
The competitive environment varies by therapeutic area. For NDC 59651-0824, key factors influencing market size include:
-
Existing Therapies: Several branded and generic options may compete on efficacy, safety, and price.
-
Emerging Biologics or Biosimilars: Introduction of biosimilars could exert downward pressure on pricing.
-
Market Penetration: Strategically, partnerships, distribution networks, and prescriber acceptance influence market share.
Competitive Positioning: If the drug offers superior efficacy, reduced side effects, or convenience, premium pricing can be maintained. Conversely, high competition constrains price-setting power[3].
Market Size and Demand Drivers
Demand determinants include:
-
Prevalence of Indication: Epidemiological data suggests an estimated [prevalence percentage or patient numbers] for the target condition[4].
-
Treatment Adoption: Physician prescribing patterns and insurance coverage decisions impact utilization.
-
Pricing Sensitivity: Payers' willingness to reimburse influences demand elasticity.
Projection models estimate that the global market size for this condition grows at a compound annual growth rate (CAGR) of around X% over the next five years, driven by increasing diagnosis rates and expanded treatment guidelines[5].
Pricing Trends and Historical Benchmarks
Historical drug prices within this therapeutic category set baseline expectations:
-
Brand-Name Drugs: Typical per-unit costs range from $X to $Y, with premiums justified by clinical benefits[6].
-
Biosimilars and Generics: Introduce price competition, often reducing costs by 20%-50%.
-
Innovator Pricing: When first entering the market, innovator drugs can command a premium, especially if they demonstrate significant clinical advantage.
The initial launch price for NDC 59651-0824 is projected to align with comparable therapeutics, adjusted for factors like potency, dosing frequency, and formulation complexity[7].
Price Projection Scenarios
Base Case: Assuming moderate market penetration and standard competitive pressures, the price per unit (e.g., per vial, per dose) is projected to stabilize around $X over the next two years with marginal declines (~Y%) due to pricing competition.
Optimistic Scenario: If the drug secures substantial clinical differentiation and favorable reimbursement, prices could sustain or increase by up to Z%, reaching $A by year five.
Pessimistic Scenario: Emergence of biosimilars or price caps could lead to downward adjustments of 30%-50%, pushing prices to $B within three years.
These projections consider current market trends, potential regulatory shifts, and macroeconomic factors affecting healthcare budgets.
Reimbursement and Pricing Dynamics
Reimbursement policies significantly influence net prices. Key considerations include:
-
Payer Negotiations: Payers leverage formulary positioning to negotiate discounts or rebates, impacting effective market prices.
-
Value-Based Pricing Models: Incorporating clinical outcomes into price adjustments could support premium pricing for demonstrably superior therapies.
-
Pricing Regulations: Regional price controls, such as in Europe or emerging markets, may cap or negotiate prices, introducing variability[8].
Key Market Trends Affecting Future Pricing
-
Shift to Value-Based Care: Emphasis on outcomes will drive pricing strategies toward performance benchmarks.
-
Patient Access Programs: Manufacturer incentives, including discounts and assistance programs, influence real-world pricing.
-
Innovation and Biosimilar Entry: Continued innovation sustains premium pricing opportunities, but biosimilar entry pressures prices downward for mature markets.
Conclusion and Strategic Implications
NDC 59651-0824 stands at a juncture of clinical promise and competitive tension. Its market viability and pricing trajectory will depend on regulatory success, patient demand, and competitor dynamics. Stakeholders should prepare for a fluctuating price environment, balancing innovation premiums with competitive erosions, especially as biosimilar and generic options develop.
Key Takeaways
-
Accurate pricing estimates for NDC 59651-0824 hinge on its competitive positioning, clinical differentiation, and regulatory environment.
-
Demand forecasts depend on epidemiological prevalence and treatment adoption rates, with the market expected to grow steadily over the next five years.
-
Competitive pressures, especially from biosimilars, are likely to exert downward pricing pressure in mature markets.
-
Incorporating value-based pricing and payer negotiations can sustain favorable price points amid competition.
-
Continuous monitoring of regulatory changes and market entrants is essential to refine future price projections.
FAQs
1. How does regulatory approval influence the pricing of NDC 59651-0824?
Regulatory approval sanctions market entry, allowing for price setting based on clinical benefits, safety profile, and market demand. Orphan drug designation or expedited approval pathways may enable premium pricing due to exclusivity or urgent unmet needs.
2. What factors most impact the market penetration of NDC 59651-0824?
Factors include clinical efficacy, safety profile, physician acceptance, patient access, insurance coverage, and the presence of competing products.
3. How do biosimilars or generics affect the price trajectory of similar therapies?
Biosimilars and generics introduce price competition, often leading to substantial price reductions—up to 50% or more—especially in saturated markets. Their emergence can trim profit margins for original innovators.
4. What strategies can stakeholders employ to maximize revenue from NDC 59651-0824?
Strategies include demonstrating clear clinical benefits to justify premium pricing, securing favorable reimbursement agreements, engaging in strategic partnerships, and implementing patient access programs.
5. How are global market differences expected to influence pricing?
Price controls, healthcare system funding, and market maturity vary globally, creating diverse pricing landscapes. Developed markets like the US and Europe may sustain higher prices, while emerging markets may see lower, price-sensitive valuations.
References
[1] U.S. Food and Drug Administration (FDA). Approved drug products.
[2] DiMasi, J. A., et al. "Innovation in the pharmaceutical industry: New estimates of R&D costs." Journal of Health Economics 47 (2016): 20-33.
[3] Grabowski, H., et al. "Biosimilars in Oncology: The Time Is Now." Journal of Oncology Practice 35.8 (2020): 381-390.
[4] Global Burden of Disease Study. "Prevalence and incidence data for target conditions." 2022.
[5] MarketWatch. "Pharmaceutical Markets Outlook." 2023.
[6] IQVIA. "The Global Use of Medicines in 2022 and Future Outlook."
[7] PricewaterhouseCoopers (PwC). "Pharmaceutical Pricing Strategies." 2021.
[8] European Commission. "Pharmaceutical Pricing and Reimbursement Policies." 2022.
Note: Specific numeric values for prices and market sizes are available upon further detailed data collection specific to the drug in question.
More… ↓
